As reported by Yahoo Finance, the U.S. Food and Drug Administration (FDA) has accepted for review two applications from Sandoz for generic versions of tirzepatide, a GLP-1–based therapy currently marketed by Eli Lilly. If authorized, these products could introduce early competition in the rapidly expanding market for treatments targeting type 2 diabetes and obesity.
Sandoz indicated that its proposed medications are intended to address the same clinical indications as Lilly’s branded tirzepatide therapies, including glycemic control in diabetes and long-term weight management. The company emphasized that its formulations could become among the first generic tirzepatide options available to patients in the United States once market conditions permit.
Although the regulatory timeline remains uncertain, the FDA typically completes reviews of standard drug applications within approximately 10 months of submission. The progress of these filings will be closely monitored given the commercial significance of GLP-1 receptor agonists and related agents.
Tirzepatide, currently sold under the brand names Mounjaro and Zepbound, remains under patent protection in the U.S. until 2036. However, generic manufacturers and other developers are already positioning themselves to capture future demand in the lucrative weight-loss and metabolic disease market.
Separately, Sandoz has demonstrated its broader strategy of entering high-demand therapeutic segments. The company previously announced plans to introduce non-branded versions of Novo Nordisk’s diabetes treatment Ozempic in Canada, though no recent updates on that launch have been provided.
The FDA’s review of Sandoz’s tirzepatide candidates marks a notable development as competition begins to take shape in one of the pharmaceutical industry’s fastest-growing categories.
